1. jamanetwork.com

    Findings In this cohort study of 281 793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe COVID-19 illness, compared with 246 076 who had no treatment, nirmatrelvir use in the acute phase (n = 35 717) was associated with reduced risk of PCC, including reduced risk of 10 of 13 post-acute sequelae in ...
  2. pubmed.ncbi.nlm.nih.gov

    Jun 1, 2023Importance: Post-COVID-19 condition (PCC), also known as long COVID, affects many individuals. Prevention of PCC is an urgent public health priority. Objective: To examine whether treatment with nirmatrelvir in the acute phase of COVID-19 is associated with reduced risk of PCC. Design, setting, and participants: This cohort study used the health care databases of the US Department of Veterans ...
  3. sciencedirect.com

    Jan 1, 2025Postacute sequelae may be related to physiological stress of hospitalization; risks of post-infectious sequelae after COVID-19 predominantly accrue in hospitalized cases [1, 2, 5, 15, 16] and is broadly comparable with that observed after hospitalization for other acute infections, such as influenza and sepsis [24, 25].
  4. pubmed.ncbi.nlm.nih.gov

    The effect of nirmatrelvir plus ritonavir (NMV-r) on post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection remains unknown. This retrospective cohort study utilized data from the TriNetX Research Network. We identified nonhospitalized adult patients with COVID-19 receiving a diagnosis …
  5. pubmed.ncbi.nlm.nih.gov

    Interpretation: This study showed extended benefits of nirmatrelvir-ritonavir for reducing the risk of post-acute inpatient death as well as cardiovascular and respiratory complications among patients admitted to hospital with COVID-19. Further research is essential to uncover the underlying mechanisms responsible for these observed negative ...
  6. sciencedirect.com

    Oct 1, 2024Lam and colleagues 4 previously identified an elevated risk of 13 long-term post-acute sequelae among patients with COVID-19 in Hong Kong, where almost all the patients with COVID-19 had their first infection during the omicron epidemic. Therefore, our aim was to use real-world data to examine the association between nirmatrelvir-ritonavir ...
  7. thelancet.com

    6 days agoPost-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+β7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nature Commun. 2023; 14, 1772. ... Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023; 183:554-564. Crossref. Scopus (135) PubMed.
  8. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC9840225

    Dear Editor, We read with interest the recent meta-analysis assessing the clinical efficacy and safety of nirmatrelvir plus ritonavir (NMV-r) in the treatment of patients with COVID-19. 1 Based on the analysis of 13 studies involving 186,306 patients, the authors concluded that NMV-r was effective in reducing the mortality (odds ratio [OR], 0.12; 95% CI, 0.04-0.36) and the risk of ...
  9. pmc.ncbi.nlm.nih.gov

    In this cohort study of 281 793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe COVID-19 illness, compared with 246 076 who had no treatment, nirmatrelvir use in the acute phase (n = 35 717) was associated with reduced risk of PCC, including reduced risk of 10 of 13 post-acute sequelae in various ...
  10. pubmed.ncbi.nlm.nih.gov

    Objectives: Significant heterogeneity has been reported in cohort studies evaluating the impact of early oral antiviral treatment on preventing post-acute sequelae after COVID-19 (PASC). We evaluated the impact of early nirmatrelvir/ritonavir on risk of post-acute cardiovascular, neurological, respiratory and autoimmune diagnoses, as well as post-acute symptoms amongst older Singaporeans.

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX